Analyst consensus rating
Humacyte Analyst Rating: Buy
Direct answer
Humacyte's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $1.63.
Forecast evidence checked October 17, 2026.
Get free Humacyte email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.43
- Average price target
- $1.63
- High price target
- $4.00
- Low price target
- $0.50
- Low target gap
- +16.6%
- Target upside
- +278.8%
- High target gap
- +832.4%
- Target range width
- 815.9%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Humacyte?
Humacyte has a verified Buy consensus. The same dataset has an average price target of $1.63.
How far are Humacyte's low and high targets from the recorded price?
The low target implies +16.6%, while the high target implies +832.4%.
How many analysts are included in Humacyte's consensus?
The verified consensus includes 6 analysts.
How is Humacyte's target upside or downside calculated?
The average target of $1.63 is divided by the recorded price of $0.43, then one is subtracted to produce +278.8%. This does not guarantee a future return.
When was Humacyte's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.